Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis

---

Brown J. W. L., Coles A., Horakova D., Havrdova E., Izquierdo G., Prat A., ...Daha Fazla

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, cilt.321, sa.2, ss.175-187, 2019 (SCI-Expanded, Scopus)

• Yayın Türü: Makale / Tam Makale
• Cilt numarası: 321 Sayı: 2
• Basım Tarihi: 2019
• Doi Numarası: 10.1001/jama.2018.20588
• Dergi Adı: JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
• Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
• Sayfa Sayıları: ss.175-187
• Karadeniz Teknik Üniversitesi Adresli: Evet

Özet

IMPORTANCE Within 2 decades of onset, 80% of untreated patients with relapsing-remitting multiple sclerosis (MS) convert to a phase of irreversible disability accrual termed secondary progressiveMS. The association between disease-modifying treatments (DMTs), and this conversion has rarely been studied and never using a validated definition.